John Curnutte

From 2011 through his retirement in May 2019, Dr. Curnutte served as Executive Vice President of Research and Development at Portola Pharmaceuticals, Inc., a biopharmaceutical company developing product candidates for thrombosis and other hematologic diseases. He remains as a consultant to Portola. From 2008 to 2010, Dr. Curnutte served as the Chief Executive Officer of 3-V Biosciences, Inc., a biotechnology company focused on host-directed antiviral medicines. Prior to that, from 2000 to 2008, he served as CEO of DNAX and President of Schering-Plough Biopharma, a biopharmaceutical subsidiary of Schering-Plough Corporation. During that time, he also served as Senior Vice President of Discovery Research at Schering Plough Research Institute, a pharmaceutical and healthcare company. From 1993 to 2000, Dr. Curnutte was the Head of Immunology at Genentech, Inc., a biotechnology company. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. He was an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff from 1993 to 2013. Since 2017, Dr. Curnutte has served as a member of the Board of Directors of Pliant Therapeutics, Inc., a human therapeutics company developing novel therapies for the treatment of fibrosis. Since 2019, he has also served as a member of the board of directors of Orchard Therapeutics, a company focused on ex vivo autologous bone marrow gene therapy. From 2015 to 2016, Dr. Curnutte served as a member of the Board of Directors of Diadexus, Inc., a cardiovascular diagnostics company. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from Harvard University and an M.D. and a Ph.D. in Biological Chemistry from Harvard Medical School.